AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33454817 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-first therapy
Number of subjects: 318
Study 33454817 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 318
Study 33455802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%, 200 ml (400 mg) injected peri-articularly in each knee
Number of subjects: 28
Study 33455902 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartBot app intervention for 21 days, 30 minutes daily.
Number of subjects: 88
Study 33455902 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 88
Study 33455928 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 0
Study 33458803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi)
Number of subjects: 893
Study 33458803 — intervention group
Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 893
Study 33459029 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularized logistic regression classifier based on 73 hybrid ECG features
Number of subjects: 1244
Study 33459029 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of 73 hybrid ECG features
Number of subjects: 1244
Study 33459029 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrics of nondipolar electrical dispersion, ventricular activation time, QRS and T axes and angles, principal component analysis ratio of ECG waveforms
Number of subjects: 1244
Study 33459278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghya Bharari Ekatra (GBE) intervention delivered over 6 weekly sessions by lay peer educators; included components on relationship quality, resilience, communication, self-esteem, sexual communication, and norms around IPV.
Number of subjects: 40
Study 33459278 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving information on IPV support services alone.
Number of subjects: 40
Study 33459278 — intervention group
Group type: EXPERIMENTAL
Intervention: GBE intervention
Number of subjects: 40
Study 33459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Standalone text messaging obesity intervention (Charge)
Number of subjects: 32
Study 33459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging components (various experimental conditions)
Number of subjects: 32
Study 33459599 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS)
Number of subjects: 172
Study 33459599 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 172
Study 33460002 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 937
Study 33460002 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir + Thymosin-alpha1 (ETV + Thy-α1)
Number of subjects: 937
Study 33460002 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine + Adefovir (LAM + ADV)
Number of subjects: 937
Study 33460016 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered semaglutide 7 mg
Number of subjects: 0
Study 33460016 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered semaglutide 14 mg
Number of subjects: 0
Study 33460016 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study 33460048 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release methylphenidate
Number of subjects: 497
Study 33461041 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 853
Study 33461041 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) in ULD subgroup
Number of subjects: 853
Study 33461307 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day of long chain n-3 polyunsaturated fatty acids (fish oil capsules) for 6 weeks
Number of subjects: 130
Study 33461307 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 130
Study 33461313 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy
Number of subjects: 129
Study 33461313 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group: adults without OSA)
Number of subjects: 129
Study 33461506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CogniFit)
Number of subjects: 234
Study 33461506 — intervention group
Group type: COMPARATOR
Intervention: Entertainment gaming (SIMS 4)
Number of subjects: 234
Study 33461506 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 234
Study 33461512 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 2
Study 33463373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m²)
Number of subjects: 0
Study 33463384 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow and deep breathing intervention, details on dosage and duration not available.
Number of subjects: 0
Study 33463384 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study 33463536 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy twins
Number of subjects: 0
Study 33463536 — intervention group
Group type: COMPARATOR
Intervention: Allergic twins
Number of subjects: 0
Study 33463537 — intervention group
Group type: EXPERIMENTAL
Intervention: SEC23B-deficient T cells
Number of subjects: 0
Study 33463537 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells from patients with congenital dyserythropoietic anemia II (CDAII)
Number of subjects: 0
Study 33463537 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo rescue of murine KO by expression of Sec23a
Number of subjects: 0
Study 33463535 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted immunomodulatory therapies
Number of subjects: 0
Study 33463535 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved drugs for IPF
Number of subjects: 0
Study 33463542 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-associated microbes from the Clostridia class enriched in healthy twins
Number of subjects: 0
Study 33463542 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation probiotic therapies
Number of subjects: 0
Study 33463551 — intervention group
Group type: EXPERIMENTAL
Intervention: Early T follicular helper cell activity
Number of subjects: 0
Study 33463551 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-specific MBCs from spontaneous resolvers
Number of subjects: 0
Study 33463551 — intervention group
Group type: COMPARATOR
Intervention: E2-specific MBCs from chronically infected subjects
Number of subjects: 0
Study 33463681 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated digital health tools (checklist and video) administered on a mobile device via a patient portal or web-based survey at least 24 hours prior to anticipated discharge.
Number of subjects: 484
Study 33464021 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV), Lamivudine (3TC), and Lopinavir/Ritonavir (LPV/r) syrup for 48 weeks according to WHO weight band dosing.
Number of subjects: 52
Study 33464027 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolor confocal scanning laser ophthalmoscopy
Number of subjects: 30
Study 33464027 — intervention group
Group type: COMPARATOR
Intervention: Color fundus photography
Number of subjects: 30
Study 33464147 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab treatment
Number of subjects: 0
Study 33464215 — intervention group
Group type: EXPERIMENTAL
Intervention: EaseVRx (8-week skills-based VR program)
Number of subjects: 180
Study 33464215 — intervention group
Group type: COMPARATOR
Intervention: Sham VR (control condition)
Number of subjects: 180
Study 33464575 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (with or without additional clot removal strategies)
Number of subjects: 1943
Study 33464621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 1800
Study 33464621 — intervention group
Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 1800
Study 33464953 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow left ventricular assist devices (CF-LVADs)
Number of subjects: 12
Study 33465022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis/cannabinoids
Number of subjects: 0
Study 33465022 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatments (e.g. opioids, NSAIDs)
Number of subjects: 0
Study 33465034 — intervention group
Group type: EXPERIMENTAL
Intervention: TraceTogether contact tracing app
Number of subjects: 505
Study 33465034 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral modifications due to the pandemic (e.g., using hand sanitizers, avoiding public transport, preferring outdoor venues)
Number of subjects: 505
Study 33465034 — intervention group
Group type: COMPARATOR
Intervention: Demographic and situational characteristics
Number of subjects: 505
Study 33465252 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-targeted radionuclide therapy (TRT)
Number of subjects: 215
Study 33465704 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 56
Study 33466285 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocannabinoidome (eCBome) subsets
Number of subjects: 0
Study 33466285 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive regression models based on selected endocannabinoids
Number of subjects: 0
Study 33466285 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive approaches
Number of subjects: 0
Study 33466285 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of quartiles
Number of subjects: 0
Study 33467570 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 0
Study 33467570 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 0
Study 33467875 — intervention group
Group type: EXPERIMENTAL
Intervention: First retrieval attempt
Number of subjects: 1225
Study 33467875 — intervention group
Group type: EXPERIMENTAL
Intervention: Second retrieval attempt
Number of subjects: 1225
Study 33467875 — intervention group
Group type: EXPERIMENTAL
Intervention: Third retrieval attempt
Number of subjects: 1225
Study 33467875 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion within the first 3 retrieval attempts
Number of subjects: 1225
Study 33468262 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite global symptom score for abdominal symptoms
Number of subjects: 150
Study 33468262 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal tension
Number of subjects: 150
Study 33468262 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdominal pain
Number of subjects: 150
Study 33468262 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal discomfort
Number of subjects: 150
Study 33468262 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation
Number of subjects: 150
Study 33468262 — intervention group
Group type: EXPERIMENTAL
Intervention: EULAR Sjögren syndrome disease activity index score
Number of subjects: 150
Study 33468262 — intervention group
Group type: EXPERIMENTAL
Intervention: EULAR Sjogren Syndrome Patient Reported Index (ESSPRI) symptom score
Number of subjects: 150
Study 33468262 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 150
Study 33468698 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA vaccine pBI-11 targeting HPV16 and HPV18 E6 and E7 proteins
Number of subjects: 0
Study 33468698 — intervention group
Group type: COMPARATOR
Intervention: DNA vaccine pBI-10.1 utilizing native viral sequences
Number of subjects: 0
Study 33469058 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 G52T variant (TT group)
Number of subjects: 4489
Study 33469058 — intervention group
Group type: COMPARATOR
Intervention: Other groups (GG and GT)
Number of subjects: 4489
Study 33469259 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX-101
Number of subjects: 745
Study 33469259 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 745
Study 33469316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 70 mg Q4W
Number of subjects: 550
Study 33469316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg Q4W
Number of subjects: 550
Study 33469316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 280 mg Q2W
Number of subjects: 550
Study 33469316 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 550
Study 33469316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (all doses)
Number of subjects: 550
Study 33469316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 550
Study 33469328 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine biosimilar Ezelin (EZL)
Number of subjects: 133
Study 33469328 — intervention group
Group type: COMPARATOR
Intervention: Originator insulin glargine Lantus (LAN)
Number of subjects: 133
Study 33469351 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy + moderate-intensity aerobic exercise
Number of subjects: 60
Study 33469351 — intervention group
Group type: COMPARATOR
Intervention: Placebo low-level laser therapy + moderate-intensity aerobic exercise
Number of subjects: 60
Study 33469439 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 care units (CCU)
Number of subjects: 1244
Study 33469439 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 care units (NCCU)
Number of subjects: 1244
Study 33469439 — intervention group
Group type: EXPERIMENTAL
Intervention: CCU + NCCU
Number of subjects: 1244
Study 33469439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 1244
Study 33469439 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 1244
Study 33469542 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal chest imaging findings
Number of subjects: 125
Study 33469542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low peripheral blood oxygen saturation
Number of subjects: 125
Study 33469542 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately-elevated body temperature
Number of subjects: 125
Study 33469542 — intervention group
Group type: COMPARATOR
Intervention: Normal chest imaging findings
Number of subjects: 125
Study 33469542 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged after improvement
Number of subjects: 125
Study 33469542 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferred for advanced care
Number of subjects: 125
Study 33469662 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma diagnostic and prognostic biomarkers of cerebral cavernous angioma with symptomatic hemorrhage (CASH)
Number of subjects: 0
Study 33469662 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative combinations of plasma proteins and micro-ribonucleic acids
Number of subjects: 0
Study 33469662 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced statistical and machine learning approaches
Number of subjects: 0
Study 33469828 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently Gd-enhancing lesions (PE group)
Number of subjects: 41
Study 33469828 — intervention group
Group type: COMPARATOR
Intervention: No enhancement (NE group)
Number of subjects: 41
Study 33469828 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently Gd-enhancing lesions (PE group) in aquaporin-4-positive, first-attack, transverse myelitis or high-dose steroid treatment subgroup
Number of subjects: 41
Study 33469845 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit program (10-week group program integrating mind-body skills, pain coping, and activity monitoring with Fitbit)
Number of subjects: 4
Study 33469845 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit program
Number of subjects: 4
Study 33469852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of autologous bone marrow-derived mesenchymal stem cells (MSCs) (1 × 10)
Number of subjects: 2
Study 33469852 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study 33469905 — intervention group
Group type: EXPERIMENTAL
Intervention: POC-ECT with whole blood (WB)
Number of subjects: 40
Study 33469905 — intervention group
Group type: EXPERIMENTAL
Intervention: POC-ECT with citrated blood (CB)
Number of subjects: 40
Study 33469905 — intervention group
Group type: EXPERIMENTAL
Intervention: POC-ECT with citrated plasma (CP)
Number of subjects: 40
Study 33469905 — intervention group
Group type: EXPERIMENTAL
Intervention: DTM assay
Number of subjects: 40
Study 33470063 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg/day
Number of subjects: 19
Study 33470662 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 0
Study 33470662 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimizing time to antimicrobial therapy
Number of subjects: 0
Study 33470662 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic choice
Number of subjects: 0
Study 33470662 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial dosing
Number of subjects: 0
Study 33470662 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation of therapy
Number of subjects: 0
Study 33470662 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of duration of antimicrobials
Number of subjects: 0
Study 33470848 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (tele-ED) consultation
Number of subjects: 25
Study 33470848 — intervention group
Group type: COMPARATOR
Intervention: Non telemedicine patients
Number of subjects: 25
Study 33470897 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid topical application and 633 nm red light illumination
Number of subjects: 0
Study 33470899 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-facilitated palliative care consultations
Number of subjects: 0
Study 33470899 — intervention group
Group type: COMPARATOR
Intervention: Standard palliative care consultations (if applicable)
Number of subjects: 0
Study 33470940 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO Monitor (video game-based digital therapeutic)
Number of subjects: 100
Study 33470940 — intervention group
Group type: COMPARATOR
Intervention: Standard measures (Brief International Cognitive Assessment for Multiple Sclerosis, including SDMT and MS Functional Composite 4)
Number of subjects: 100
Study 33470940 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO Monitor performance
Number of subjects: 100
Study 33470990 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided physical activity increase
Number of subjects: 0
Study 33470990 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 0
Study 33470990 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital (pre/post dialysis) supervised exercise
Number of subjects: 0
Study 33470990 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance assessment only
Number of subjects: 0
Study 33471291 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 0
Study 33471291 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatments
Number of subjects: 0
Study 33471291 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated approaches (SBRT + systemic treatments)
Number of subjects: 0
Study 33471594 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environment in infancy
Number of subjects: 0
Study 33471827 — intervention group
Group type: EXPERIMENTAL
Intervention: PDDM model intervention
Number of subjects: 61
Study 33471827 — intervention group
Group type: EXPERIMENTAL
Intervention: PDDM model training for clinicians
Number of subjects: 61
Study 33471949 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel cisplatin 5-fluorouracil induction chemotherapy
Number of subjects: 0
Study 33472397 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time cardiac magnetic resonance (RT-CMR) exercise imaging
Number of subjects: 75
Study 33472397 — intervention group
Group type: COMPARATOR
Intervention: Right heart catheterization
Number of subjects: 75
Study 33472409 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop system for managing type 1 diabetes
Number of subjects: 39
Study 33472513 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD and insomnia group
Number of subjects: 0
Study 33472513 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 0
Study 33472545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensively monitored antiretroviral pause (IMAP)
Number of subjects: 32
Study 33472545 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline questionnaire before or after initiating IMAP
Number of subjects: 32
Study 33472545 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended responses
Number of subjects: 32
Study 33472575 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive stroke center patients
Number of subjects: 4340
Study 33472575 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stroke center patients
Number of subjects: 4340
Study 33472606 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero ZIKV exposure
Number of subjects: 235
Study 33472606 — intervention group
Group type: COMPARATOR
Intervention: ZIKV unexposed toddlers
Number of subjects: 235
Study 33472666 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 3 mg twice daily (MTD)
Number of subjects: 9
Study 33472666 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 1 mg twice daily
Number of subjects: 9
Study 33472666 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 2 mg twice daily
Number of subjects: 9
Study 33472666 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 3 mg twice daily
Number of subjects: 9
Study 33472674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi mind-body intervention
Number of subjects: 24
Study 33472674 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 24
Study 33472687 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBL®
Number of subjects: 49
Study 33472687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 33472776 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 600
Study 33473101 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen peptide-pulsed autologous dendritic cell vaccine
Number of subjects: 12
Study 33474638 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted treatment
Number of subjects: 86